Curated Information

Javascript is not enabled on this browser. This site will not work properly without Javascript.

Home

Curated Information Page

PubMed Id: 9384584

This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus^®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus^®, click here.

Kato Y, et al. (1997) BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J 16, 7054-66 9384584

S387-p - MEF2C iso3 (human)

▲

Orthologous residues

MEF2C (human): S419‑p, MEF2C iso3 (human): S387‑p, MEF2C iso4 (human): S409‑p, MEF2C (mouse): S420‑p, MEF2C iso4 (mouse): S378‑p, MEF2C (rat): S441‑p

Characterization

Enzymes shown to modify site in vitro:

Type	Enzyme
KINASE	ERK5 (human)

Upstream Regulation

Potential in vivo enzymes for site:

Type	Enzyme	Evidence	Notes
KINASE	ERK5 (human)

Treatments, proteins and their effect on site modification:

Treatments	Referenced Treatments	Manipulated Protein	Referenced Protein	Effect	Notes
serum				increase

Downstream Regulation

Effect of modification (function): activation

Comments: MEF2C activation leads to increased transcription of the c-jun gene.

Home \| Curator Login	With enhanced literature mining using Linguamatics I2E		Produced by 3rd Millennium \| Design by Digizyme
			©2003-2013 Cell Signaling Technology, Inc.